Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
McKesson is acquiring Precision Medicine Group for $2.25 billion, doubling down on oncology and clinical research. The Maryland-based firm offers clinical research, lab testing, and drug commercialization services for biotech and pharma companies. Precision will be folded into McKesson's fast-growing oncology and multispecialty unit, which saw revenue surge 33% to $14.2 billion last quarter.
McKesson is making a major move in the clinical research space, announcing a $2.25 billion deal to acquire Precision Medicine Group. The Bethesda, Maryland-based company provides clinical research, laboratory testing, and commercialization services that help biotech and pharma companies develop and launch new drugs — a natural fit for McKesson's ongoing push into higher-growth specialty businesses.
Once the deal closes, Precision will be integrated into McKesson's oncology and multispecialty unit. CEO Brian Tyler framed the acquisition as a way to enhance clinical trial execution and broaden the company's clinical service offerings. Analysts largely view it as a strategic "tuck-in" rather than a transformative bet, noting its value represents just over 2% of McKesson's market cap.
By the Numbers:
Why it matters: This deal signals a broader industry trend of healthcare distributors moving upstream into clinical research and drug development services. For oncology in particular, tighter integration between drug distribution and clinical trial infrastructure could accelerate how quickly new therapies reach patients.
